July 6, 2018 / 3:54 PM / 3 months ago

BRIEF-Cosmo Pharmaceuticals Updates On Uceris

July 6 (Reuters) - Cosmo Pharmaceuticals NV:

* ANNOUNCED THAT FDA HAS APPROVED ACTAVIS (TEVA) GENERIC VERSION OF UCERIS

* COSMO PHARMACEUTICALS - AS PATENT INFRINGEMENT TRIAL IS STILL ONGOING IN APPEAL, IF TEVA DECIDES TO LAUNCH AT RISK, SUCH LAUNCH WOULD EXPOSE TEVA TO PAY SIGNIFICANT DAMAGES

* CEO - WE WILL CONTINUE TO TENACIOUSLY DEFEND AND ENFORCE OUR PATENT RIGHTS ON UCERIS IN ORDER TO PROFIT OF EXCLUSIVITY TO ITS WIDEST EXTENT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below